Compositions and methods for treatment of colitis
    4.
    发明申请
    Compositions and methods for treatment of colitis 有权
    用于治疗结肠炎的组合物和方法

    公开(公告)号:US20060058365A1

    公开(公告)日:2006-03-16

    申请号:US10912948

    申请日:2004-08-06

    IPC分类号: A61K31/4166

    摘要: The present invention relates to the treatment of inflammatory bowel disease (IBD) and related gastrointestinal pathologies. This invention also relates to the treatment of cytokine-mediated diseases, including tumor necrosis factor-α (TNFα)-induced diseases and/or chemokine-mediated diseases. This invention also relates to treating an animal having a disease or condition associated with Toll-like receptor 4. Specifically, the present invention relates to the treatment of inflammatory bowel disease (IBD) and related gastrointestinal pathologies that are cytokine-mediated or associated with Toll-like receptor 4. More specifically, this invention is directed to methods for treating or preventing IBD and related gastrointestinal pathologies using methimazole derivatives and tautomeric cyclic thiones. This invention is also directed to pharmaceutical compositions containing methimazole derivatives and tautomeric cyclic thiones, which are useful for the treatment or prophylaxis of IBD and related gastrointestinal pathologies. This invention also relates to pharmaceutical formulations capable of inhibiting tumor necrosis factor-α (TNFα)-induced vascular cell adhesion molecule-1 (VCAM-1) expression and the resulting leukocyte-endothelial cell adhesion for the inhibition and prevention of inflammatory bowel syndrome and related gastrointestinal pathologies.

    摘要翻译: 本发明涉及炎症性肠病(IBD)和相关胃肠道病理学的治疗。 本发明还涉及细胞因子介导的疾病的治疗,包括肿瘤坏死因子-α(TNFα)诱导的疾病和/或趋化因子介导的疾病。 本发明还涉及治疗具有与Toll样受体4相关的疾病或病症的动物。具体而言,本发明涉及炎症性肠病(IBD)的治疗以及细胞因子介导或与Toll相关的相关胃肠病理 类似受体4.更具体地,本发明涉及使用甲巯咪唑衍生物和互变异构环状硫堇治疗或预防IBD和相关胃肠道病理学的方法。 本发明还涉及含有甲巯咪唑衍生物和互变异构环状硫堇的药物组合物,其可用于治疗或预防IBD和相关的胃肠道病理。 本发明还涉及能够抑制肿瘤坏死因子-α(TNFα)诱导的血管细胞粘附分子-1(VCAM-1)表达的药物制剂以及由此产生的白细胞内皮细胞粘附以抑制和预防炎症性肠综合征和 相关的胃肠道病变。

    Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion
    5.
    发明申请
    Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion 审中-公开
    甲基咪唑衍生物和互变异构环状硫堇以抑制细胞粘附

    公开(公告)号:US20050209295A1

    公开(公告)日:2005-09-22

    申请号:US10801986

    申请日:2004-03-16

    IPC分类号: A61K31/4166

    CPC分类号: A61K31/4166 Y02A50/411

    摘要: The present invention relates to novel compounds and methods of use for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. In particular, methimazole derivatives and tautomeric cyclic thiones have the ability to inhibit the adhesion and the migration of leukocytes. In addition to being active anti-inflammatories, the methimazole derivatives and tautomeric cyclic thiones and their physiologically tolerable salts, derivatives and prodrugs are generally suitable for the treatment (i.e., for the therapy and prophylaxis) of diseases that are based on the interaction between VCAM-1 and its ligands or can be influenced by an inhibition of this interaction. In particular, the methimazole derivatives and tautomeric cyclic thiones are suitable for the treatment of diseases that are caused at least partly by an undesired extent of leukocyte adhesion and/or leukocyte migration or are connected therewith, and for whose prevention, alleviation or cure the adhesion and/or migration of leukocytes should be decreased.

    摘要翻译: 本发明涉及新型化合物和用于抑制和预防细胞粘附和细胞粘附介导的病理学的方法。 本发明还涉及包含这些化合物的药物制剂及其用于抑制和预防细胞粘附和细胞粘附介导的病理学的方法。 本发明的化合物和药物组合物可用作治疗剂或预防剂。 特别地,甲巯咪唑衍生物和互变异构环状硫堇具有抑制白细胞粘附和迁移的能力。 除了是主要的抗炎药之外,甲巯咪唑衍生物和互变异构环状硫堇及其生理上可耐受的盐,衍生物和前药通常适用于基于VCAM相互作用的疾病的治疗(即治疗和预防) -1及其配体或可能受到这种相互作用的抑制的影响。 特别地,甲巯咪唑衍生物和互变异构环状硫堇适用于治疗至少部分由不期望的白细胞粘附和/或白细胞迁移程度引起的疾病或与之相关的疾病,并且为了预防,缓解或治愈粘连 和/或白细胞迁移应减少。